Download pdf
On-target off-tumor (OTOT) toxicity from HER2-targeting chimeric antigen receptor (CAR) engineered T cell therapy: current solutions
- 1 Hebei Medical University, Shijiazhuang, China
* Author to whom correspondence should be addressed.
Abstract
Breast cancer is a major threat to women's life and health, with HER2+ BC accounting for a significant proportion of cases. This subtype is characterized by aggressive behavior, a high recurrence rate, and generally poor prognosis. The efficacy of conventional HER2-CAR-T treatment for HER2-positive breast cancer is well-documented; however, it is not without its risks, particularly the potential for on-target off-tumor (OTOT) toxicity, which poses a significant threat to patient safety. This analysis examines the difficulties encountered with standard HER2-CAR-T approaches and discusses contemporary methods designed to reduce the incidence of OTOT toxicity. This review organizes the strategies into three primary methods, offering an exhaustive summary to facilitate the medical and research sectors in gaining a deeper comprehension of the present scenario and prospective advancements of HER2-CAR-T treatment. By discussing these approaches and the underlying mechanisms that make them effective, this review aims to inspire further innovation in improving existing HER2-CAR-T therapy. A thorough understanding of the current challenges and promising avenues for enhancement in HER2-CAR-T therapy is quite important for advancing future research and clinical applications.
Keywords
HER2, CAR-T cells, On-target off-tumor toxicity, Multi-antigen targeting, SynNotch
[1]. World Health Organization, 2024, https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
[2]. Wang, G., Wu, Y., Su, Y., Qu, N., Chen, B., et al. (2024). TCF12-regulated GRB7 facilitates the HER2+ breast cancer progression by activating Notch1 signaling pathway. J Transl Med, 22(1), 745. https://doi.org/10.1186/s12967-024-05536-6
[3]. Uscanga-Palomeque, A. C., Chávez-Escamilla, A. K., Alvizo-Báez, C. A., Saavedra-Alonso, S., Terrazas-Armendáriz, L. D., et al. (2023). CAR-T therapy: From the Shop to Cancer Therapy. Int J Mol Sci, 24(21): 15688. https://doi.org/10.3390/ijms242115688
[4]. Sun, M., Shi, H., Liu, C., Liu, J., Liu, X., et al. (2014). Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Breast Cancer Res, 16(3): R61. https://doi.org/10.1186/bcr3674
[5]. Cao, Y., Rodgers, D. T., Du, J., Ahmad, I., Hampton, E. N., et al. (2016). Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer. Angew Chem Int Ed Engl, 55(26): 7520-7524. https://doi.org/10.1002/anie.201601902
[6]. Hyrenius-Wittsten, A., Su, Y., Park, M., Garcia, J. M., Alavi, J., et al. (2021). SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med, 13(591): eabd8836. https://doi.org/10.1126/scitranslmed.abd8836
[7]. Hernandez-Lopez, R. A., Yu, W., Cabral, K. A., Creasey, O. A., Lopez P., et al. (2021). T cell circuits that sense antigen density with an ultrasensitive threshold. Science, 371(6534): 1166-1171. https://doi.org/10.1126/science.abc1855
[8]. Kennewick, K. T., Yamaguchi, Y., Gibson, J., Gerdts, E. A., Jeang, B., et al. (2024). Nonsignaling extracellular spacer regulates tumor antigen selectivity of CAR T cells. Mol Ther Oncol, 32(2): 200789. https://doi.org/10.1016/j.omton.2024.200789
[9]. McComb, S., Nguyen, T., Shepherd, A., Henry, K. A., Bloemberg, D., et al. (2022). Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation. Front Immunol, 13: 864868. https://doi.org/10.3389/fimmu.2022.864868
[10]. Bassan, D., Weinberger, L., Yi, J., Kim, T., Weist, M. R., et al. (2023). HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address OTOT toxicity. J Immunother Cancer, 11(12): e007426. https://doi.org/10.1136/jitc-2023-007426
[11]. Duan, Y., Chen, R., Huang, Y., Meng, X., Chen, J., et al. (2021). Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy. Cell Mol Life Sci, 79(1): 14. https://doi.org/10.1007/s00018-021-04089-x
[12]. He, H., Liao, Q., Zhao, C., Zhu, C., Feng, M., et al. (2021). Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy. J Immunother Cancer, 9(10): e002755. https://doi.org/10.1136/jitc-2021-002755
Cite this article
Ke,J. (2024). On-target off-tumor (OTOT) toxicity from HER2-targeting chimeric antigen receptor (CAR) engineered T cell therapy: current solutions. Theoretical and Natural Science,74,157-162.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of ICBioMed 2024 Workshop: Computational Proteomics in Drug Discovery and Development from Medicinal Plants
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).